Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
- Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics
- ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim?s Discovery Research organization, maintaining its innovative biotech heritage and close connections to the Medical University of Innsbruck and the regional scientific community
- Acquisition strengthens Boehringer Ingelheim?s commitment to research and development of viral-based immuno-oncology treatment options aimed at transforming the lives of patients?